best in class

Annual report ranks Houston university as the best in Texas

Rice University ranks in the top 10 universities in the country, per this new report. Photo courtesy of Rice University

There's something to be said for consistency. In a new report card from Niche.com, Rice University retains its No. 7 ranking among the best colleges in the U.S. and its No. 1 ranking among the best colleges in Texas.

Niche.com, which helps students and parents pick schools, relies on data from sources such as the U.S. Department of Education to compile its annual rankings, as well as reviews and ratings from current students, alumni, and parents.

Here are the top 10 schools in Niche.com's ranking of the country's best colleges:

  1. Massachusetts Institute of Technology
  2. Harvard University
  3. Stanford University
  4. Yale University
  5. Princeton University
  6. Duke University
  7. Rice University
  8. Brown University
  9. University of Pennsylvania
  10. Dartmouth College

Only two of the top 10 schools — Rice and Stanford — are west of the Mississippi River.

In this year's ranking, Niche.com de-emphasized the importance of SAT and ACT scores by 50 percent. In making that decision, Niche.com cited socioeconomic and racial disparities perpetuated by standardized tests, challenges making appointments for in-person tests due to COVID-19, and a rising number of institutions adopting test-optional policies.

"Our team recognizes that the COVID-19 pandemic, especially as new variants such as the delta variant arise, will continue to have an outsize impact on the college admissions process this year," Luke Skurman, founder and CEO of Niche.com, says in an August 16 news release. "We wanted to make sure our 2022 rankings reflect the current reality."

Rice is no stranger to accolades like the Niche.com ranking. It appears at No. 16 on U.S. News & World Report's most recent list of the top national universities, and at No. 16 in the most recent The Wall Street Journal/Times Higher Education rankings of top U.S. colleges. In both cases, Rice is the top-rated school in Texas.

On Niche.com's national list, the highest-ranked Texas school behind Rice is the University of Texas at Austin (No. 52). Meanwhile, UT holds the No. 14 spot nationally among the best colleges for student life, making it the top Texas school in that category.

Among nationally ranked schools, UT Austin is followed in Texas' top 10 by:

  • Texas A&M University in College Station, No. 80
  • Southern Methodist University in Dallas, No. 88
  • Trinity University in San Antonio, No. 96
  • Texas Christian University in Fort Worth, No. 115
  • Baylor University in Waco, No. 145
  • LeTourneau University in Longview, No. 162
  • Texas Tech University in Lubbock, No. 168
  • University of Texas at Dallas, No. 209

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted